The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bon
 

Amgen today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA to Zometa in preventing bone complications called skeletal-related events in 1,901 men with prostate cancer and bone metastases.

More...